Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Meetings Sponsor Program

The European Hematology Association (EHA) is a membership organization serving clinicians and researchers with an active interest in hematology in Europe and beyond. We bring together relevant stakeholders to promote excellence in patient care through education, research, and advocacy.

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more

EHA2024 Hybrid Congress

Thank you all for joining us in Madrid for the 29th European Hematology Association Congress!

The on-demand content of the EHA2024 Congress is available on the Congress platform until August 15! One more week to go, do not miss this opportunity.…

Read more

Would you sell Peripheral Blood derived Stem Cells?

There are many things that are different in the United States of America (USA) and Europe. Some of these differences are in favour of society in the USA and some in Europe.

Read more

HARMONY Alliance: 2nd General Assembly, October 23-24, 2017

The 2nd HARMONY General Assembly is organised from 23-24 October 2017 at Bayer in Berlin. The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of 51 partners.

Read more